Innovation in myeloma treatments PARP excellence!

Blood

Volumn 118, Issue 24, 2011, Pages 6234-6235

  Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRCA1 PROTEIN; DOUBLE STRANDED DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SINGLE STRANDED DNA; VELIPARIB;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CELL; CANCER INHIBITION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOTOXICITY; DISEASE CONTROL; DNA REPAIR; DNA STRAND BREAKAGE; EXCISION REPAIR; GENE LOSS; GENETIC GAIN; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; MYELOMA; NOTE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 83455220284     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-381129     Document Type: Note

References (11)

1. Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118(24):6368-6379.
2. Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-534.
3. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21(3):529-534.
4. Domagala P, Lubinski J, Domagala W. Iniparib in metastatic triple-negative breast cancer [letter]. N Engl J Med. 2011;364(18):1780; author reply, 1781.
5. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-214.
6. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
7. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB. A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res. 2009;15(2):417-419.
8. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-3417.
9. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
10. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
11. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144. (Pubitemid 47208626)